Search results
May 7, 2024 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis . It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases.
Apr 18, 2022 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
May 7, 2024 · AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
AbbVie formed a new kind of enterprise – a biopharmaceutical company – with the stability, global scale, resources and commercial capabilities of a pharmaceutical company and the focus and culture of a biotech. Since the beginning, our mission hasn't wavered.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
